Introduction to the domestic launch time and market supply situation of Bikken Pronol Tablets (Bituvi)

Biktarvy tablets (Biktarvy) have been marketed in China and are included in medical insurance, and are mainly used for the treatment of adult HIV‑1 infection. Developed by Gilead, the drug is a triple compound single-tablet preparation containing entegravir, emtricitabine and TAF, which can effectively inhibit HIV viral replication and reduce viral load. Since its approval, Bituvi has been gradually rolled out in the domestic market, mainly through tertiary hospitals and designated HIV pharmacies. Patients can use it according to medical advice after being evaluated by a doctor. The price of domestically imported drugs is about more than one thousand yuan per box (30 tablets). After medical insurance reimbursement, the patient's out-of-pocket cost will vary depending on region and hospital policies.

In terms of market supply, the original imported version of Bituvit is mainly imported. Since the drug is an imported preparation, its supply is affected by international logistics and hospital procurement policies. Patients in some areas may need to make an appointment in advance or contact the hospital pharmacy to ensure drug supply. At the same time, HIV specialized hospitals and some community pharmacies in major cities in the country have also begun to provide the drug, allowing patients to obtain treatment more stably. For clinicians, stability of drug supply is critical to long-term control of HIV infection and maintenance of virological suppression.

In addition, India and other countries have launched a regular generic version of Bituvi.30The price of a tablet is only a few hundred yuan, and the drug ingredients are basically the same as the original drug. This type of generic drugs has obvious advantages in price, but they are mainly circulated in the local market, and there are compliance issues when used in mainland China. If patients consider using overseas generic drugs, they should evaluate the safety and efficacy through formal channels and under the guidance of a doctor to avoid risks caused by unknown sources of drugs.

Generally speaking, Bituvi has been legally marketed in China and is included in medical insurance. Patients can obtain drug treatment through regular hospitals and pharmacies and enjoy the policy convenience of medical insurance reimbursement. The price of original drugs is relatively high, but the market supply is relatively stable. For patients in need, they should reasonably choose a medication plan based on doctor's advice, medical insurance policies and their own economic conditions. At the same time, attention should be paid to the formality of the source of drugs to ensure the safety and continuity of treatment.

Reference:https://reference.medscape.com/